Bristol-Myers Squibb Co vs GraniteShares 2x Long COIN Daily ETF — how do they compare? Bristol-Myers Squibb Co trades at $63.88 (market cap $129.94B), while GraniteShares 2x Long COIN Daily ETF trades at $4.05. The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while GraniteShares 2x Long COIN Daily ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, GraniteShares 2x Long COIN Daily ETF nearer its low. Which is the better fit depends on your goals.
| BMY | CONL | |
|---|---|---|
Market Cap | $129.94B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $65.89 | $48.70 |
52-Week Low | $42.60 | $3.93 |
Enterprise Value | $163.92B | — |
Dividend Yield | 3.96% | — |
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.
The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.
CONL, the GraniteShares 2x Long COIN Daily ETF, trades at $4.175, up 2.08% on the day, but remains in a pronounced bearish technical trend with all moving averages signaling sell. The ETF is designed to deliver twice the daily return of Coinbase stock (COIN), which has experienced significant volatility. Recent news highlights substantial losses, with CONL down 67% year-to-date as of June 2026, illustrating the high-risk nature of leveraged products.
The outlook is highly speculative and carries extreme risk due to the ETF's daily reset leverage, which can lead to rapid value erosion during volatile periods. Investment opportunity is limited to aggressive, short-term traders who can manage the volatility tax. The primary risk is the structural decay associated with daily rebalancing in a choppy market for the underlying asset.
Trailing returns across standard periods
Latest headlines on both assets
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →CONL is a leveraged ETF that seeks to provide two times (2x) the daily performance of Coinbase Global (COIN) stock. It is designed for investors seeking magnified short-term exposure to the price movements of Coinbase.
Read more on CONL →